Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SplicingCodes is a small private U.S.-based biotech/bioinformatics company focused on RNA splicing analysis, fusion transcript detection, and hereditary fusion gene research. The company appears to operate closely with BioTailor and has published work and patent filings around computational methods for identifying fusion transcripts from RNA-seq data and for analyzing splicing codes. Its core value proposition is a platform/algorithmic approach rather than a conventional therapeutic pipeline, with applications in cancer genomics, inherited disease research, and biomarker discovery. Publicly available evidence suggests the company is research-stage and not a clinical-stage drug developer. SplicingCodes is most closely associated with founder Degen Zhuo and Miami/Palmetto Bay, Florida.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SplicingCodes.